Snowflake Score | |
---|---|
Valuation | 4/6 |
Future Growth | 3/6 |
Past Performance | 3/6 |
Financial Health | 3/6 |
Dividends | 0/6 |
Cencora, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$242.53 |
52 Week High | US$243.78 |
52 Week Low | US$156.90 |
Beta | 0.45 |
1 Month Change | 2.56% |
3 Month Change | 19.09% |
1 Year Change | 58.65% |
3 Year Change | 105.03% |
5 Year Change | 216.95% |
Change since IPO | 129.93% |
Recent News & Updates
Recent updates
Shareholder Returns
0HF3 | GB Healthcare | GB Market | |
---|---|---|---|
7D | 2.1% | -0.6% | 2.3% |
1Y | 58.6% | -21.2% | 4.9% |
Return vs Industry: 0HF3 exceeded the UK Healthcare industry which returned -21.2% over the past year.
Return vs Market: 0HF3 exceeded the UK Market which returned 4.9% over the past year.
Price Volatility
0HF3 volatility | |
---|---|
0HF3 Average Weekly Movement | 2.5% |
Healthcare Industry Average Movement | 7.7% |
Market Average Movement | 4.7% |
10% most volatile stocks in GB Market | 11.3% |
10% least volatile stocks in GB Market | 2.5% |
Stable Share Price: 0HF3 has not had significant price volatility in the past 3 months.
Volatility Over Time: 0HF3's weekly volatility (3%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2001 | 44,000 | Steve Collis | https://www.cencora.com |
Cencora, Inc. sources and distributes pharmaceutical products. The company’s U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.
Cencora, Inc. Fundamentals Summary
0HF3 fundamental statistics | |
---|---|
Market cap | US$48.32b |
Earnings (TTM) | US$1.87b |
Revenue (TTM) | US$271.58b |
25.9x
P/E Ratio0.2x
P/S RatioIs 0HF3 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
0HF3 income statement (TTM) | |
---|---|
Revenue | US$271.58b |
Cost of Revenue | US$262.43b |
Gross Profit | US$9.15b |
Other Expenses | US$7.28b |
Earnings | US$1.87b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | 9.37 |
Gross Margin | 3.37% |
Net Profit Margin | 0.69% |
Debt/Equity Ratio | 450.3% |
How did 0HF3 perform over the long term?
See historical performance and comparison